Reprogrammed Interchange LLC has demonstrated a consistent and pronounced selling bias in its recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 44 transactions, the entity has exclusively sold shares, with no purchases recorded. The total sell value amounts to $27,680,032.78, all concentrated in a single company, Vor Biopharma Inc. (ticker: VOR). This activity is particularly notable in the latter half of October 2025, where Reprogrammed Interchange executed 25 sell transactions within a span of just over two weeks, from October 2 to October 21, 2025. The transactions vary widely in size, ranging from $6,015 on October 21 to $2,056,471.83 on October 8, indicating a strategic liquidation of holdings rather than a uniform sell-off.
The frequency and magnitude of these sales suggest a deliberate reduction in Reprogrammed Interchange’s stake in Vor Biopharma. Notably, several high-value transactions occurred on consecutive days, such as the $1,567,364.97 and $461,117.61 sales on October 15, followed by a $1,020,786.83 sale on October 14. This pattern underscores a sustained effort to divest from the company. While the filings provide no insight into the rationale behind these transactions, the data clearly highlights Reprogrammed Interchange’s significant and ongoing exit from its position in Vor Biopharma, marking a notable shift in its investment strategy.
AI-assisted summary